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Urological Effects of Ketamine 
Abuse
John Shung-Lai Leung and Wai-Kit Ma
Abstract
Emerging evidence has shown that long-term and chronic ketamine use or abuse 
can lead to damages in the urinary tract, a spectrum of clinical presentations from 
mild irritative lower tract symptoms to painful gross haematuria and renal dam-
ages. First reported by a Hong Kong group of urologists in 2007, the phenomenon 
has since then been identified worldwide. Most of the ketamine abusers were ado-
lescents and young adults, and the symptomatology resembled those of chemical 
cystitis or interstitial cystitis. Endoscopic features of ulcerative cystitis, radiological 
features of thickened and contracted bladder wall with or without obstruction to 
upper urinary tract, and histopathological features of inflammation and fibrosis 
and urothelial metaplasia changes were described. With increasing clinical experi-
ence in managing this group of patients, clinical pathways and medical and surgical 
treatment options have been developed. Animal studies on the effects of ketamine 
exposure on the urinary system have also been conducted to help us understand the 
underlying pathophysiology for this distinct entity.
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1. Introduction
Ketamine is listed in the WHO Essential Medicines List since 1985 as an anaesthetic 
and analgesic. Unlike other commonly used anaesthetic agents, ketamine does not tend 
to cause respiratory depression or hypotension, making it ideal for use as a general 
sedative and in veterinary medicine [1].
However, ketamine is also a drug of abuse. The United Nation’s World Drug 
Report 2019 shows that ketamine has been the dominant hallucinogenic seized 
by authorities globally, accounting for 87% of such seizures in the past 5 years 
[2]. In 2017, the global quantity of ketamine seized was approximately 11,000 
kilogrammes, the majority of which was in Asia [3]. Most ketamine seized, in 
the order of descending quantity, was reported by mainland China, followed by 
Taiwan, Hong Kong, Malaysia, Myanmar, Thailand, the United Kingdom, India, 
and the Netherlands [3]. In Taiwan, ketamine has been the most frequently abused 
illicit drug since 2006. The volume of seizures there grew from 916 kg in 2009 to 
1187 in 2010 [4]. However, ketamine is becoming more and more popular not only 
in Southeast Asia but in Europe as well. The number of ketamine users in the United 
Kingdom grew from 85,000 in 2006 to 113,000 in 2008, becoming the fourth most 
popular illicit drug among UK clubbers [5]. Its popularity could be explained by its 
low market price among recreational drugs and also the difficulty in cracking down 
on its trafficking, as it is produced legally for medical use [6].
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The chronic and illicit use of ketamine is associated with urinary tract damages. 
Structural damage to the bladder, ureters, and kidneys has been demonstrated 
in numerous animal and human studies. Patients usually present to the urologi-
cal service with symptoms such as urinary frequency, haematuria, and dysuria. 
Management is multidisciplinary, as a big part of treatment success lies not only in 
urological interventions but also in successful abstinence.
2. Epidemiology of ketamine-associated cystitis
The exact prevalence of ketamine-associated cystitis is difficult to ascertain, 
as most users are reluctant to seek medical attention despite symptoms. A study in 
Taiwan conducted in 2019 by Li et al. reported that whilst 84% of chronic ketamine 
abusers demonstrated urinary tract symptoms, only 48% sought treatment [7]. A sur-
vey involving 3806 participants in the United Kingdom by Winstock et al. found that 
26.6% of ketamine users report urinary symptoms and that the symptoms are signifi-
cantly related to both frequency and duration of use [8]. Similarly, Pal et al. from the 
United States conducted a survey involving 18,802 participants which reported a 30% 
prevalence of lower urinary tract symptoms (LUTS) among recent ketamine users [9].
Lower urinary tract symptoms, as well as dysuria and haematuria, are the most 
common symptoms caused by chronic ketamine abuse. LUTS in the setting of 
ketamine cystitis usually comprises urinary frequency, feeling of incomplete bladder 
emptying, and nocturia. More than 50% of users complain of urinary frequency after 
using ketamine for about 2 years [7]. The severity and number of symptoms are corre-
lated with not only the duration of use but also the route of administration. Ketamine 
may be cut up into a powder form before being inhaled or smoked with pipe-like 
devices. Snorting causes significantly more symptoms than smoking. This is possibly 
due to a higher amount of ketamine entering the circulation via the nasal mucosa [7].
The combined use of ketamine with other substances such as marijuana and 
3,4-methylenedioxy-methamphetamine (MDMA) has also been found to significantly 
increase the severity of LUTS. Marijuana enhances the expression of cannabinoid 
receptors CB1 and CB2, which are found in the human bladder urothelium [10]. This 
is implicated in the worsening of storage symptoms such as frequency and urgency. 
The mechanism through which MDMA exacerbates LUTS remains to be elucidated.
3. Pathogenesis of ketamine cystitis
A number of mechanisms have been proposed to explain the pathogenic effects 
of ketamine on the urinary system. These include (1) direct toxicity of ketamine or 
its metabolites on the bladder tissues; (2) microvascular changes in the bladder and 
kidneys by ketamine or its metabolites; and (3) delayed (type IV) hypersensitivity 
against the urothelium due to ketamine or its metabolites [11]. Infection is unlikely 
to play a role in the primary pathogenesis of ketamine cystitis, as the vast majority 
of patients do not have a positive urine bacterial culture. As of yet, there has not 
been a single conclusive theory on the mechanism of ketamine-induced cystitis.
In vitro studies on human urothelial cells have demonstrated dose-dependent 
toxicity of ketamine to human urothelial cells. The damage is carried out by both 
ketamine itself and its primary metabolite (norketamine) [12]. Norketamine is gen-
erated as ketamine undergoes hepatic metabolism. Both ketamine and norketamine 
are subsequently excreted in the urine. Ketamine and norketamine are equally toxic 
to the urothelium in in vitro studies, but norketamine remains in the urine for longer 
than ketamine, and hence norketamine may be accountable for more of the damage 
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done [13]. As with other toxic exposures, daily exposure has been found to be more 
damaging than a one-off exposure. The accepted anaesthetic dosage of ketamine for 
human medical use is 0.5–2 mg/kg, but much higher concentrations are abused in 
recreational use (up to 20 g per day in some users) [13]. As aforementioned in the 
previous section, it also takes approximately 2 years of abuse before cystitis symp-
toms arise. Therefore, as ketamine is used at much lower doses as well as frequency 
in the context of anaesthesia as compared to daily abuse, the medical use of ket-
amine for one-off anaesthesia is less likely to cause significant ketamine cystitis.
The hypothesis that ketamine and norketamine exert a direct effect on the 
urothelium is based on the knowledge that both chemicals are excreted by the urine 
and have a long contact time with the urothelium (ketamine 5 days, norketamine 
6 days) after ingestion [14].
The urinary tract from the renal pelvis to the proximal urethra is covered by 
the urothelium, a highly specialised transitional epithelium capable of stretching 
to accommodate various degrees of distension in response to urine volume. The 
urothelium comprises three layers—superficial, intermediate, and basal. Under the 
urothelium lies the submucosa, then the detrusor muscle, and then the adventitia.
Classic histological changes found in ketamine cystitis include denudation of 
the urothelium, as well as inflammatory changes including oedematous vessels, and 
infiltration by eosinophils and T-lymphocytes [15]. The affected urothelium loses 
its superficial layer (which provides a barrier function), thus exposing the stroma 
to further insults from urinary ketamine and norketamine. This may be one of the 
mechanisms by which ketamine causes cystitis and the resultant symptoms. Some 
of these histological changes are similarly seen in interstitial cystitis (chronic blad-
der pain in the absence of an identifiable aetiology) [16]. Additionally, haematoxy-
lin and eosin staining in the urothelium affected by ketamine cystitis may in some 
cases display apparent dysplastic changes with the loss of epithelial cohesion. Such 
changes mimic the histology of carcinoma in situ, and hence the clinical history of 
ketamine abuse should alert the clinician or pathologist to the possibility of misdi-
agnosis of carcinoma in situ [12].
The infiltration by T-lymphocytes suggests that a delayed (type IV) hypersen-
sitivity reaction to ketamine may also play a role in the pathogenesis of ketamine 
cystitis [17]. This is because T-lymphocytes are heavily implicated in type IV 
hypersensitivity reaction, and it is known that type IV hypersensitivity reactions 
occur only after prolonged exposure to the causative agent. This reaction conforms 
to the temporal profile of the development of ketamine cystitis, where symptoms 
usually develop only after 2 years of abuse.
4. Clinical presentation
The irritative effects of ketamine on the urinary system, especially the bladder, 
produce myriad symptoms. These include:
• Urinary frequency
• Feeling of incomplete bladder emptying
• Nocturia
• Urinary urgency
• Urge incontinence
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• Haematuria
• Suprapubic pain or ‘bladder pain’
The typical complaint from the affected patients is ‘painful, small voids’, closely 
mimicking that of interstitial cystitis. These symptoms typically develop after 
2 years of ketamine abuse. A study in Hong Kong by Ng et al. has demonstrated 
the relative prevalence of symptoms as follows: urgency (92%), frequency (84%), 
nocturia (88%), dysuria (86%), and haematuria (68%) [18]. The most bothersome 
symptoms reported by users are typically urinary frequency, nocturia, and urgency. 
This is because of the need of frequency visits to the bathroom, which interferes 
significantly with their daily activities [7].
The clinician may evaluate symptoms using standardised methods such as 
frequency-voiding charts (also known as a ‘bladder diary’) and questionnaires 
such as the Pelvic Pain and Urgency/Frequency (PUF). A frequency-voiding chart 
involves the patient recording the volume of every fluid intake and void and also 
instances and degrees of urge incontinence, if any. Reviewing a frequency-voiding 
chart allows the patient to communicate effectively with the clinician the frequency 
and nocturia experienced. Ketamine cystitis typically produces a low-compliance 
bladder, manifesting as frequency, low-volume voids. Urge incontinence is the sud-
den and compelling desire to pass urine that is difficult to defer and is accompanied 
by involuntary leakage.
The Pelvic Pain and Urgency/Frequency questionnaire is a symptom score ques-
tionnaire developed and validated for the diagnosis of interstitial cystitis [19]. As 
mentioned, interstitial cystitis produces symptoms and histological changes in the 
bladder akin to those found in ketamine cystitis, and studies have validated the use 
of this questionnaire to score patients experiencing symptoms of ketamine cystitis 
[18]. The questionnaire includes eight questions evaluating daytime frequency, 
nocturia, pelvic pain, urinary urgency, the degree to which these symptoms bother 
the patient, and sexual function. PUF generates a symptom score and bother score, 
which total at 35. In a patient with history of significant ketamine abuse, a score 
of ≥15 indicates the presence of significant cystitis symptoms, thus leading to the 
diagnosis of ketamine cystitis. The PUF is a useful tool not only for the diagnosis 
of ketamine cystitis but also for symptom quantification so that its severity and 
response to treatment could be monitored over time.
5. Clinical investigation findings
Cystoscopy, computed tomography (CT), ultrasonography, and pyelography 
are examples of investigations that may demonstrate the structural damage 
implicated in ketamine cystitis [20]. Cystoscopy reveals inflammatory changes 
such as telangiectasia (indicative of neovascularisation), ulceration, or even 
petechial haemorrhage in severe cases. Biopsies of the affected bladder urothe-
lium will reveal histological changes mentioned earlier in the chapter, including 
denuded epithelium and infiltration by eosinophils and lymphocytes. Computed 
tomography may show bladder wall thickening and peri-vesical stranding, both of 
which are indicative of chronic inflammation of the bladder wall (Figure 1). Upper 
tract damage usually manifests itself as unilateral or bilateral hydronephrosis, 
with ureteric wall thickening, or luminal narrowing and strictures. CT, pyelog-
raphy, and ultrasound are all suitable modalities to demonstrate hydronephrosis 
(Figures 2–4). CT and pyelography have the additional benefit of evaluating the 
exact level of ureteric stricturing.
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Figure 1. 
Contrast CT scan image showing a thickened and contracted bladder in a patient with a 7-year history of 
ketamine abuse.
Figure 2. 
Reconstructed contrast CT urogram showing bilateral hydronephrosis and hydroureter down to the level of the 
vesicoureteric junctions. The bladder also appears small with generalised wall thickening. This patient has an 
8-year history of ketamine abuse.
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Apart from assessing the degree of structural damage, the functional capacity of 
the urinary system should also be assessed. Urodynamic studies, such as video cys-
tometrogram, reveal reduced bladder capacities, reduced bladder compliance, and 
sometimes detrusor overactivity even at low bladder volumes. Bladder capacities of 
Figure 3. 
This is an antegrade pyelogram of a patient suffering from ketamine cystitis. Contrast is injected through the 
percutaneous nephrostomy. There is hydronephrosis and a contrast upholding at the level of the L3 vertebra. 
This is suggestive of a ureteric stricture at that level causing hydronephrosis.
Figure 4. 
Ultrasound image of the left kidney of a patient with ketamine cystitis complicated by acute left pyelonephritis. 
This patient had a background of ketamine cystitis with bilateral hydronephrosis. She presented acutely with 
left loin pain and fever. The ultrasound image shows debris in the chronically dilated renal pelvis. This is 
compatible with acute pyelonephritis complicating ketamine cystitis. A combination of chronic obstruction and 
vesicoureteral reflux has likely contributed to the development of upper tract infection.
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ketamine cystitis patients are typically <150 ml, and detrusor overactivity has been 
shown to be evident at bladder volumes as low as 14 ml [21]. This means that such 
patients will not only complain of very frequent but small voids, they are also likely 
to experience urge incontinence. One can see how disabling such symptoms are 
from these investigation findings (Figures 5–7).
Renal impairment can be reflected from raised serum creatinine or impaired 
creatinine clearance and estimated glomerular filtration rate. Renal impairment 
may stem from vesicoureteral reflux (VUR) due to chronic reduction in bladder 
Figure 5. 
Cystometrogram (filling phase) of a patient with a 10-year history of ketamine abuse. First desire to void was 
recorded at 14 ml of bladder filling. Also note the multiple spikes at the lowermost tracing indicative of detrusor 
overactivity. (Pves, intravesical pressure; Pabd, intra-abdominal pressure; Pdet, subtracted detrusor pressure of 
Pves–Pabd).
Figure 6. 
Cystometrogram (filling phase) of the same patient after 3 years of abstinence. First desire to void at 51 ml. 
Note the difference in the scale of the x-axis denoting volume. The detrusor overactivity has also dampened, as 
shown by the smoother Pdet tracing.
Creatinine - A Comprehensive Update
8
compliance. VUR can be demonstrated on video cystometrogram as a reflux of con-
trast material from the bladder up to the ureters. VUR predisposes the upper tract 
from urinary tract infections, increasing the risk of recurrent pyelonephritis and 
resultant renal scarring (Figure 2). Hydronephrosis as a result of ureteric narrow-
ing is also a cause of renal impairment in these patients. Ureteric narrowing is likely 
secondary to urinary ketamine and its metabolites causing transmural inflammation 
and swelling or even fibrosis and strictures (Figure 8).
Papillary necrosis may be seen on renal ultrasound or on contrast studies such as 
an intravenous urogram or computed tomography [11]. The contrast material fills 
necrotic cavities located in the renal papillae. Sometimes, sloughed necrotic mate-
rial may pass into the ureter, causing obstruction, and appear as a filling defect.
Figure 8. 
Contrast CT scan image of a patient with more than 3 years of ketamine abuse, showing bilateral atrophic 
kidneys and hydronephrosis. This patient required bilateral percutaneous nephrostomies (also seen on this 
image) for upper tract urinary diversion.
Figure 7. 
Cystometrogram (filling phase) of the same patient after 8 years of abstinence. First desire to void at 75 ml. 
Much improved bladder compliance as shown by the relatively smooth Pdet tracing.
9Urological Effects of Ketamine Abuse
DOI: http://dx.doi.org/10.5772/intechopen.91283
6. Management
6.1 Abstinence and a multidisciplinary approach
The management of ketamine cystitis aims at abating the debilitating urinary 
symptoms and preventing further damage to the urinary tract. The most important 
components of the management plan therefore lie in early diagnosis and early 
abstinence, as this aims to effectively remove ketamine and its metabolites from 
the urinary system before irreparable damage to the urinary system sets in. A 
large-scale study involving more than 1000 ketamine users reported that up to 
50% of users report symptomatic improvement after cessation of use. Urinary 
frequency has been shown to be the first symptom to improve [8]. That said, as 
with any detoxification program, psychosocial challenges pose a big barrier to 
long-term abstinence. It is therefore imperative that the clinician solicits help from 
relevant parties such as social workers, clinical psychologists, or even psychiatrists 
to form a multidisciplinary approach in managing these patients [22]. This process 
involves first identifying those suffering from ketamine cystitis, then explaining 
the relationship between ketamine use and cystitis, and finally embarking on the 
detoxification journey. As mentioned earlier in the chapter, the PUF scale serves 
as a standardised and validated means of identifying ketamine users suffering 
from cystitis. Success in multidisciplinary management has been demonstrated by 
outreach teams comprising urologists, psychiatrists, social workers, and nurses in 
Hong Kong [23].
6.2 Oral agents
Although the precise mechanism of injury in ketamine cystitis has yet to be 
elucidated, it is clear that it involves inflammation of the urothelium akin to that of 
interstitial cystitis. Medications that aim to reduce inflammation, such as nonste-
roidal anti-inflammatory drugs (NSAIDs) and glucocorticoids, have thus been 
studied in the treatment of ketamine cystitis symptoms. Other treatment regimens 
involving the use of antibiotics, anti-muscarinic agents, and beta-3 agonists have 
also been examined. However, the results from the medication therapy have been 
suboptimal overall [24].
Medication therapy may not result in significant improvements in LUTS for 
these patients, but analgesics should still be employed generously. This is because 
ketamine itself possesses analgesic properties, and therefore abstinence after long 
periods of abuse may produce pain akin to a withdrawal effect. Analgesics such as 
paracetamol, phenazopyridine, or even narcotic analgesics such as tramadol may 
be used on top of NSAIDs in high doses as pain relief during the initial period of 
detoxification [25].
6.3 Intravesical therapies
Ketamine and its metabolites cause denudation of the urothelium, exposing the 
underlying submucosa and stroma of the bladder wall to further toxic damage. This 
produces the typical LUTS as well as the structural changes such as wall thickening 
and reduction in compliance. This has prompted investigations into the effective-
ness of intravesical therapies that aim to restore the integrity of the urothelium so 
that the underlying tissue may no longer be exposed to the toxicities of ketamine 
and its metabolites. Intravesical instillation of a glycosaminoglycan, such as hyal-
uronic acid or chondroitin sulphate, has been proposed to reconstitute the barrier 
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function provided by the urothelium and enhance healing. Reports of significant 
reductions in symptoms in patients treated with weekly intravesical instillations 
of hyaluronic acid or chondroitin sulphate have been published recently [26]. 
These patients not only reported a reduction of LUTS, but follow-up cystoscopy 
with biopsies showed decreased inflammatory cell infiltration, less inflammatory 
hypervascularity, as well as regeneration of the urothelium [27].
Cystoscopic injection of botulinum toxin into the bladder wall, followed 
by hydrodistension, is another intravesical treatment that has been shown to 
relieve symptoms of ketamine cystitis [28]. Botulinum toxin type A inhibits the 
presynaptic release of neurotransmitters such as acetylcholine, thus inactivating 
neuromuscular junctions and reducing detrusor activity. The patient is typically put 
under spinal anaesthesia, and a cystoscope is then advanced into the bladder. 20 ml 
of botulinum toxin type A at a concentration of 200 IU in 20 ml is then injected 
into 40 points in the bladder wall. There is currently no standard protocol for the 
technique of hydrodistension, but authors have performed it by filling the bladder 
with saline under a pressure of 80 cmH2O, at a volume of 150–200 ml, for a dura-
tion of 5 minutes [29].
6.4 Surgical therapies
The bladder in a patient with severe ketamine cystitis is thickened and fibrotic 
and has poor compliance. Apart from severe LUTS, these changes may also 
cause vesicoureteral reflux and upper tract damage. Such patients are at risk of 
chronic renal failure. Surgical treatment in the form of augmentation cystoplasty 
is therefore an option to increase the capacity and compliance of the bladder, 
so that symptomatic improvement and upper tract protection could be brought 
about through a single procedure. Techniques vary, but an option is to use a 25 cm 
segment of the ileum and sew it to a surgically created clam-like opening of the 
bladder in order to augment its volume and compliance [30]. Contraindications 
to augmentation cystoplasty using bowel include any condition that renders the 
bowel abnormal at the baseline, for example, inflammatory bowel disease (Crohn’s 
disease, ulcerative colitis) and previous gut resection (such that further resec-
tion may predispose the patient to malabsorption or even short gut syndrome). 
Another alternative is to use a portion of the stomach, termed gastrocystoplasty. 
This has its own issues, as the hydrochloric acid produced by the stomach mucosa 
may cause haematuria-dysuria syndrome, peptic ulceration in the bladder, and 
alkalosis. Complications include a mortality rate of up to 2.7%, small bowel 
obstruction, fistulation, and renal failure (due to the reabsorption of urinary 
waste through the bowel segment). Some patients may furthermore require 
clean intermittent catheterisation to more effectively empty the bladder. Patient 
selection is paramount when considering augmentation cystoplasty for ketamine 
cystitis patients. Failure of abstinence after surgery results in rapid reabsorption 
of ketamine from the urine through the bowel segment. Ketamine and its metabo-
lites are hence recirculated, excreted in the urine again, and once again exerting 
their toxic effects on the urothelium. Augmentation cystoplasty with bowel may 
therefore even accelerate upper tract damage should the patient fail to abstain from 
ketamine postoperatively. The patient should also be willing to comply with clean 
intermittent self-catheterisation should it be required [30].
An alternative surgical strategy is an ileal conduit [31]. This involves brining 
both the ureters to an opening in the abdominal wall through a surgically created 
segment of the ileum. This obviates the need for clean intermittent catheterisation 
and offers quicker postoperative recovery. However, as this is an incontinent type of 
urinary diversion, the patient would have to live with a lifelong urostomy bag.
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6.5 Upper tract protection
Some patients present with bilateral hydronephrosis with or without impair-
ment of renal function. This could be due to vesicoureteral reflux or ureteric 
strictures. As most patients with ketamine cystitis are young, it is of paramount 
importance that their upper tract is protected to prevent chronic renal disease. 
Methods to achieve this include percutaneous nephrostomy and ureteral stenting. 
Percutaneous nephrostomy involves placing a plastic tube through the skin into 
the renal pelvis so that the urine produced by the kidney may drain through the 
tube into an external bag instead of being trapped in the obstructed system. The 
drainage of the urine through nephrostomy tubes into an external bag also reduces 
the LUTS from ketamine cystitis, as there is significantly less urine entering the 
bladder. Disadvantages include inconvenience, as well as nephrostomy tube-related 
Figure 9. 
Clinical pathway for the management of ketamine cystitis (adapted from Ma et al.) [22].
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complications such as frequent dislodgement, and blockage. The inconvenience 
associated with the use of a nephrostomy tube is due not only to the presence of the 
tube exiting the loin but also to the bag to which it is connected. Another way of 
ensuring upper tract drainage is by retrograde stenting [32]. Double J stents can be 
inserted via a cystoscope to ensure ureteric patency. This method obviates the need 
for external tubes and bags, but as urine is allowed to flow into the bladder, LUTS 
may persist. Additionally, some patients may also suffer from stent symptoms, 
which include LUTS due to the stent tips in the bladder irritating the urothelium.
6.6 Clinical pathway
Urologists in Hong Kong such as Ma et al. have established a clinical pathway 
in order to guide and standardise the management of ketamine cystitis [22]. 
Patients going through such a clinical pathway will receive a full workup of 
the extent of their ketamine cystitis and complications and receive treatment 
accordingly (Figure 9).
7. Challenges
The treatment of ketamine cystitis revolves heavily around abstinence. However, 
addiction and withdrawal symptoms, as well as the socioeconomic factors that con-
tribute to the persistence of ketamine abuse, are not the only factors that hamper 
successful abstinence.
Abstinence from ketamine in the presence of ketamine cystitis is made more 
difficult by bladder pain and dysuria. As ketamine exhibits analgesic effects, it 
paradoxically suppresses the bladder pain and dysuria caused by ketamine cystitis. 
Subsequently, the cessation of ketamine use will unmask more intense cystitis 
symptoms. If such symptoms are inadequately controlled by more effective anal-
gesics, the patient may be driven to use ketamine as a means to control the cystitis 
symptoms. Such a pattern of abstinence, failure of symptomatic control, and 
relapse creates a vicious cycle. It is therefore important to prescribe the patient with 
adequate analgesia according to the analgesic ladder to effectively suppress bladder 
pain and dysuria. The flip side of this is that the patient may in turn become depen-
dent on the prescribed analgesics, especially if opioids are used [25].
Failure of abstinence in patients who have received surgical treatment such 
as augmentation cystoplasty may prove to be detrimental. As mentioned in the 
Management section, the reabsorption of ketamine and its urinary metabolites via 
the bowel segment used for augmentation cystoplasty may accelerate damage to 
the upper urinary tract, making the surgical treatment counterproductive. Correct 
patient selection for surgical treatment weighs heavily upon the urologist [31].
Upper tract protection by means of bilateral percutaneous nephrostomies (PCNs) 
may be the last resort for patients with identifiable hydronephrosis and impaired 
renal function [33]. However, as most ketamine cystitis patients are young and ambu-
latory, bilateral PCNs prove to be a cumbersome and a general nuisance. Not only are 
the nephrostomy tubes and bags inconvenient to live with, they also come with issues 
such as dislodgement or tube blockage. Tube-related issues may require hospitalisa-
tion for the revision of the nephrostomies, which adds not only to patient dissatisfac-
tion but also to overall healthcare costs. With such inconvenience, the patient may 
be deterred from complying with having bilateral PCNs and in turn exposes himself 
to risks of chronic kidney disease and eventual dialysis dependence. Dialysis depen-
dence in this age group makes the employment difficult, which then contributes to a 
lack of socioeconomic support and again makes abstinence a challenge.
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8. Conclusions
Long-term ketamine abuse leads to the development of ketamine cystitis. 
Symptoms are debilitating and interfere significantly with the patient’s daily activi-
ties. Furthermore, the upper tract may also suffer from irreversible damage, such 
as ureteric stricturing and finally chronic renal failure. Management of ketamine 
cystitis starts with its identification. This could be achieved using standardised 
symptom score questionnaires in known abusers of ketamine. Investigations such as 
blood tests, computed tomography, and cystometrogram are useful to characterise 
and delineate the extent of ketamine cystitis and its sequelae. The cornerstone of 
effective treatment is abstinence. This is done via a multidisciplinary approach 
involving urologists, psychiatrists, social workers, and other relevant disciplines. 
Intravesical therapies, such as hyaluronic acid instillation and botulinum toxin 
injection, are emerging options that have shown promising results. Upper tract pro-
tection in the form of long-term percutaneous nephrostomies may save the patient 
from suffering from chronic renal failure.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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